# Neuroceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuroceuticals

- Industry: Medical Devices & Equipment
- Headquarters: Tokyo, Japan
- Website: www.nci-md.com
- Total disclosed funding: $3M
- Latest round: Series B (Jul 31, 2017)
- Investors on record: 3

## About

Neuroceuticals Inc., based in Tokyo, Japan, manufactures advanced medical devices, focusing on innovative solutions for cardiac health, particularly through its vagus nerve stimulation catheter system.Founded in 2009, Neuroceuticals Inc. specializes in creating medical devices aimed at improving cardiac health. The company has engaged in five deals, with its most recent funding round occurring on January 18, 2022, when it raised JPY 183.60 mn in a Series B round led by Daiwa Corporate Investment, bringing the total amount raised to JPY 183.60 mn. Shinya Miike is the current CEO, overseeing operations as the company targets healthcare providers across North America and Asia-Pacific.Neuroceuticals specializes in advanced medical devices, particularly focusing on its core product, the vagus nerve stimulation catheter system. This innovative system is designed to protect cardiac muscle and mitigate the effects of heart failure, addressing critical healthcare needs. It stimulates the vagus nerve to regulate heart function and targets a wide range of healthcare providers, hospitals, and clinics globally, especially in North America and Asia-Pacific. The company has partnered with established firms to enhance distribution capabilities.Neuroceuticals generates revenue through direct sales of its proprietary medical devices, primarily the vagus nerve stimulation catheter system, to healthcare institutions. The business model includes partnerships with larger medical device companies, facilitating broader distribution. Transactions occur on a B2B basis, with hospitals and medical facilities placing bulk orders. While specific pricing details are proprietary, the financial structure relies on direct sales and potential revenue-sharing agreements with distribution partners, supporting the company's growth within the healthcare sector.Following the recent funding round on January 18, 2022, Neuroceuticals plans to utilize the JPY 183.60 mn raised to develop new medical equipment. The company aims to expand its market presence, particularly in North America and Asia-Pacific, by introducing innovative products designed to address specific healthcare needs. The management is focused on launching these new medical devices within the next few years, leveraging the recent investment to bolster its product development and market expansion strategies.

## Funding rounds

- Series B, Jul 31, 2017, $1.7M — Daiwa Corporate Investment
- Series A, Aug 31, 2016, $1.4M — SMBC Venture Capital, Mizuho Capital

## Investors

- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series A
- Daiwa Corporate Investment (https://capitalatlas.ai/funds/daiwa-corporate-investment) — Series B